You are here

Eylea

Allergan’s eye contender cannot knock Eylea off its perch

EP Vantage

Sun, 07/22/18 - 12:24 pm

wet age-related macular degeneration

Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label

Market Realist

Thu, 06/21/18 - 09:38 am

diabetic retinopathy

3 Reasons Regeneron Stock Could Start Climbing Again

Yahoo/Motley Fool

Sun, 05/6/18 - 01:14 pm

Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Endpoints

Mon, 04/30/18 - 09:04 pm

wet age-related macular degeneration

Novartis sues Regeneron over manufacturing methods

Biopharma Dive

Thu, 03/29/18 - 09:14 pm

drug manufacturing

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Xtalks

Tue, 03/20/18 - 09:45 am

diabetic retinopathy

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

Endpoints

Mon, 03/19/18 - 11:44 am

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Motley Fool

Wed, 03/7/18 - 09:22 am

Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases

Fierce Pharma

Thu, 02/22/18 - 11:14 pm

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

Endpoints

Mon, 02/12/18 - 09:49 am

bispecific antibodies

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

Drug Delivery Business News

Thu, 01/4/18 - 11:01 am

Momenta Pharmaceuticals

diabetic macular edema

wet age-related macular degeneration

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

Endpoints

Mon, 11/27/17 - 09:18 am

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?

Motley Fool

Tue, 06/27/17 - 09:45 am

Clovis Oncology

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Endpoints

Tue, 06/20/17 - 08:51 am

Regeneron posts mixed Q1 results, Eylea growth slows

Drug Delivery Business News

Sun, 05/7/17 - 10:13 am

Clearside enrolls first patient in phase III trial of Zuprata combination therapy

Drug Delivery Business News

Mon, 02/20/17 - 09:53 am

Clearside Biomedical

retinal vein occulsion

Regeneron revenue rises 11.7 pct on Eylea eye drug

Yahoo/Reuters

Thu, 02/9/17 - 11:18 am

Biotechs line up to tap growing ophthalmics market

BioPharma Dive

Thu, 12/22/16 - 10:25 am

Ophthalmic Drugs Market

Ocular Therapeutix

Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea

Endpoints

Thu, 10/13/16 - 10:41 am

Ocular Therapeutix

Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista

Yahoo/Benzinga

Tue, 10/4/16 - 10:17 am

clinical trials

Pages